from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2zOQAm6 on July 19, 2018 at 04:23PM Bloomberg News has published a live pricing index for some of the most used and popular drugs across the globe as it attempts to measure the success of President Donald Trump’s effort to cut drug prices. According to Bloomberg, the index […]
from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2NZMSJs on July 19, 2018 at 03:52PM ECRI Institute announced plans this week to continue providing the centralized source of medical guidelines originally offered by the now-shuttered National Guideline Clearinghouse. According to a press release, The nonprofit was called upon by the government 20 years ago to develop […]
from AcademyHealth Blog at http://bit.ly/2uKhHsX on July 19, 2018 at 03:29PM Spurring Innovation: The Role of Child Health Policy The last 12 months has seen its share of health policy discourse, including discussions on topics that previously enjoyed bi-partisan support. Recent debates about federal and state spending, entitlements, and other issues traditionally fraught with political […]
from Market Design at http://bit.ly/2L7fvXs on July 19, 2018 at 01:49PM You will be shocked to learn that doctors and transplant centers respond to incentives in their effort to get scarce organ transplants for their own patients… Here’s a recent OPTN/UNOS white paper on the subject, concerning the waitlist for organs (such as hearts) for […]
from The Incidental Economist at http://bit.ly/2L81ed7 on July 19, 2018 at 11:22AM That’s the title of a new NEJM Perspective by Michael Chernew and me. After crunching the numbers, our argument is that for long term cost control we will probably need to address growth in per capita health care utilization. The easy “solutions” won’t […]
from OHE News at http://bit.ly/2JG4IxW on July 19, 2018 at 11:08AM What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?
from News at http://bit.ly/2JG4IxW on July 19, 2018 at 09:28AM The high cost of drugs for rare diseases (‘orphan drugs’) has generated considerable debate. While there is debate in the economic literature over whether a premium should be paid for ‘rarity’, these drugs are reimbursed with high prices in many countries. The question then arises […]